PectaSol vs Other Modified Citrus Pectin Brands: Compared

PectaSol modified citrus pectin appears in 7+ peer-reviewed human clinical trials since 1999, the most-studied MCP brand in the United States. A landmark 14.4 g/day prostate cancer trial showed slowed PSA doubling time in 70% of patients.

This article compares PectaSol-C to other MCP supplements on molecular weight, clinical evidence, and modification method — explaining what the research record means for buyers considering alternative brands.

Key Takeaways

• PectaSol-C is cited in 7+ peer-reviewed human MCP trials since 1999.
• Molecular weight under 10,000 Da defines PectaSol's galectin-3 binding affinity.
• Esterification under 5% determines binding strength across all 12 brands.
• Generic MCP with verified COA can match PectaSol specs at 50% cost.
• Enzymatic modification preserves galactose units across 3 manufacturing steps reliably.

For a full overview of Modified Citrus Pectin — including how it works, benefits, dosage, and safety — see our Modified Citrus Pectin Guide.

What Is PectaSol-C and Who Makes It?

PectaSol-C® is a proprietary modified citrus pectin formulation developed by Isaac Eliaz, MD, and manufactured by EcoNugenics. EcoNugenics holds patents on the specific enzymatic modification process used to bring PectaSol's molecular weight below 10,000 Daltons — well within the absorption threshold that allows MCP fragments to enter systemic circulation and block galectin-3.

The formulation was first introduced in the 1990s following preclinical work showing that low-molecular-weight pectin fragments inhibit galectin-3 and reduce tumor metastasis in animal models. Since then, EcoNugenics has co-authored the majority of published human trials using MCP.

• Developer: Isaac Eliaz, MD; manufactured by EcoNugenics since the 1990s.
• Patents: proprietary enzymatic hydrolysis for sub-10 kDa molecular weight.
• Clinical track record: majority of published human MCP trials used PectaSol-C.

PectaSol-C is available as powder and capsule. The powder form was used in most clinical trials due to dosing flexibility — the prostate cancer PSA studies required 14.4 g/day, which is practical only in powder format.

PectaSol-C in Published Research: The Clinical Record

The clinical evidence base for MCP is largely a PectaSol-C evidence base. Most published human trials used EcoNugenics' specific formulation — not modified citrus pectin as a generic category.[1]Guess BW et al. — Modified Citrus Pectin Slows PSA Doubling Time in Men With Prostate Cancer — Prostate Cancer Prostatic Dis — PubMed View source

The major published trials with PectaSol-C span four research areas:

• Prostate cancer PSA slowing — 14.4 g/day for 12 months; 70% of patients showed increased PSA doubling time (Guess et al., 2003).[2]MCP Phase II Prostate Cancer Trial — PubMed View source
• Advanced prostate cancer — 5 g three times daily; improved progression-free survival vs baseline (Yan & Katz, 2010).[3]PectaSol-C Suppresses Cancer Cell Invasion — PubMed View source
• Heavy metal chelation — 15 g/day with alginate; significant urinary reductions in lead, arsenic, and cadmium (Eliaz et al., 2007).[4]MCP and Urinary Excretion of Toxic Elements — PubMed View source
• Immune modulation — galectin-3 inhibition activating NK cells and T-helper cells across multiple mechanisms.[5]Pleiotropic Effects of MCP — PubMed View source

No other single MCP brand has a comparable volume of published human trials using its specific formulation. This doesn't mean PectaSol is inherently superior — it means buyers have no published data to verify whether competing products produce the same outcomes.

Key Quality Specifications Across All MCP Brands

Regardless of brand, three specifications determine whether an MCP product matches the galectin-3–inhibiting formulations used in published research:. Compare with our breakdown of the MCP clinical benefits.

• Molecular weight — must be under 10,000–15,000 Daltons. Regular citrus pectin is 60,000–300,000 Daltons. Products without a confirmed molecular weight on the COA may be regular pectin sold as modified.
• Degree of esterification (DE) — under 5% (low-methoxyl). This determines how well the galactose chains bind to galectin-3's carbohydrate-recognition domain. High-methoxyl MCP (DE >50%) has reduced binding affinity and does not match the researched formulations.
• Modification method — enzymatic hydrolysis at controlled pH preserves galactose chain integrity better than heat or acid hydrolysis. Lower-cost brands sometimes use pH or heat processing that may alter galactose content unpredictably.

A brand that meets all three specifications can provide galectin-3 inhibition comparable to PectaSol-C — though no head-to-head trial exists to confirm equivalence. Generic alternatives like Remedy's 1,000 mg MCP capsules publish COAs verifying under-15-kDa specs at $0.48 per gram.

PectaSol-C vs Other MCP Brands: Side-by-Side

Does It Have to Be PectaSol-C?

No. The clinical rationale for MCP depends on molecular weight and galactose structure — not on the brand that holds patents for a specific modification process. A competing product that documents matching specifications on its COA should produce comparable galectin-3 inhibition in principle.

• What matters for activity: molecular weight under 15 kDa and degree of esterification under 5% — both verifiable on a Certificate of Analysis.
• What does not matter: the patent holder of a specific enzymatic process — any depolymerization that hits the same spec range delivers comparable galectin-3 binding.
• What buyers cannot verify: whether a generic's published spec matches each individual batch — PectaSol-C ships batch-specific COAs; most generics publish only an average.

The practical challenge is verification. PectaSol-C's advantage is transparency — the specs are published, independently verified, and supported by trials using the actual product. A generic brand claiming equivalent specs requires buyers to verify those claims through COA documentation rather than relying on published clinical data.

How to Evaluate Any MCP Product

Use this framework to evaluate any MCP brand, including alternatives to PectaSol-C:

• Step 1 — Request the COA. Ask the manufacturer for a third-party Certificate of Analysis. No COA = disqualifying factor for a galectin-3 application.
• Step 2 — Verify molecular weight. Confirmed under 15,000 Daltons (ideally under 10,000 Da to match PectaSol-C's specs).
• Step 3 — Check degree of esterification. Under 5% (low-methoxyl) for optimal galectin-3 binding affinity.
• Step 4 — Identify modification method. Enzymatic hydrolysis preserves galactose chain structure better than heat or acid processing.
• Step 5 — Verify heavy metal testing. The MCP itself must be tested for lead, arsenic, cadmium, and mercury — critical for a product used in detox contexts.

Among available products, Remedy's Nutrition Modified Citrus Pectin is enzymatically processed to low molecular weight, non-GMO, vegan, and third-party tested — formulated to the molecular specifications described in the galectin-3 research.[8]MCP Chemical Analysis and Galectin-3 Inhibition — PubMed View source[9]MCP Inhibits Galectin-8 — PubMed View source[10]Pectin Bioactive Polysaccharide — PubMed View source

For a complete evaluation framework, see how to choose a quality modified citrus pectin supplement.

Frequently Asked Questions

Related Reading

• How to Choose a Quality Modified Citrus Pectin Supplement
• Modified Citrus Pectin Dosage and Usage Guide
• Modified Citrus Pectin and Cancer Research
• Is Modified Citrus Pectin Safe for Everyone?
• Organic Modified Citrus Pectin: Certification and Quality